South Med J 85(12):1255–1256ĭoyle GJ, O’Donnell SC, McDonald JR, et al. Trulzsch DV, Penmetsa A, Karim A, Evans DA (1992) Gastrografin-induced aspiration pneumonia: a lethal complication of computed tomography. Sung JP, O’Hara VS, Lee CY (1977) Barium peritonitis. There is no significant difference in palatability between iopamidol and iohexol, supporting the use of iopamidol as a viable alternative to iohexol as an oral contrast agent. One-way ANOVA equality of means test of just iopamidol, iohexol, and barium does not reject the hypothesis that means are equal ( F* = 1.778 and p = .174). No difference was found between iopamidol and iohexol ( p = .959). Post hoc testing demonstrates Gastrografin to be significantly less preferred to barium ( p = .000) and iohexol ( p = .012).
One-way ANOVA equality of means test shows rejection of the hypothesis that the means are equal ( F* = 6.550, p = .000). Participants scored palatability on a continuous scale from 0 to 40 (0 = intolerable, 10 = unpleasant but tolerable, 20 = neutral, 30 = kind of like, 40 = strongly like).
#Deltagraph trial#
This was a blinded and randomized trial in which fifty healthy subjects taste tested iopamidol (Isovue, Bracco Diagnostics), iohexol (Omnipaque, GE Healthcare), diatrizoate meglumine and diatrizoate sodium solution (Gastrografin, Bracco Diagnostics), and barium sulfate suspension 2.1% w/v, 2.0% w/w (READI-CAT2, E-Z-EM).
The objective of this study is to compare the palatability of iopamidol and iohexol.
0 kommentar(er)
